Nihon Koden Acquires U.S. Software Developer Neurotronics
This article was originally published in PharmAsia News
Nihon Koden announced Dec. 26 the company will acquire 100 percent of shares of U.S. software developing company Neurotronics by Dec. 31. Nihon Koden's move is to further strengthen its sleep respiratory business, which the company hopes to reach ¥1 billion in sales by March 2009 and ¥2 billion by March 2011. The company will utilize sleep brain wave analysis technology developed by Neurotronics and develop products to treat sleep apnea syndrome. Based in Gainesville, Florida, Neurotronics has 18 employees. Nihon Koden estimates that Polysomnography all-night sleep polygraph testing that uses brain wave analysis software to diagnose SAS will spread rapidly in the future. (Click here for more - Japanese language
You may also be interested in...
The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval.
When asked about an inspector general report that found hospitals are struggling with tests and resources, and are looking to the federal government to help facilitate more efficient distribution of medical devices to fight the COVID-19 crisis, President Trump attacked the report as a political hit from an Obama holdover.
Japanese medical device manufacturer Terumo Corp. promoted senior management execs; MiMedx Group, developer of human placental tissue allografts, raised exec to CFO; and more.